The listing application submitted by Shenzhen YimuFeng Biotechnology Co., Ltd. (referred to as YimuFeng Bio) for its initial public offering on the Hong Kong Stock Exchange has lapsed. The prospectus, filed on February 13, 2026, reached its six-month validity period on August 13, 2026, becoming invalid.

At the time of the filing, Huatai International served as the sole sponsor. According to the previously disclosed prospectus, YimuFeng Bio is a globally leading innovative cell therapy company.

The company's core product, IMC002, is a potential best-in-class anti-CLDN18.2 CAR-T cell therapy candidate. This therapy is the second-fastest progressing solid tumor CAR-T cell therapy candidate globally in clinical development and is currently in a pivotal clinical stage (Phase III clinical trial).